Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OGEN 
Oragenics Inc (OGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: OGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.99% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.25M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 0.65 | 52 Weeks Range 1.03 - 36.90 | Updated Date 08/29/2025 |
52 Weeks Range 1.03 - 36.90 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -19.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-08 | When - | Estimate - | Actual -3.1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -245.73% | Return on Equity (TTM) -748.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5642085 | Price to Sales(TTM) 89.28 |
Enterprise Value 5642085 | Price to Sales(TTM) 89.28 | ||
Enterprise Value to Revenue 105.83 | Enterprise Value to EBITDA 0.21 | Shares Outstanding 4127170 | Shares Floating 4027543 |
Shares Outstanding 4127170 | Shares Floating 4027543 | ||
Percent Insiders 2.41 | Percent Institutions 2.56 |
Upturn AI SWOT
Oragenics Inc
Company Overview
History and Background
Oragenics, Inc. is a biotechnology company focused on developing novel antibiotics to combat infectious diseases and on developing effective treatments for oral mucositis. Founded to pursue novel antibiotics, they've shifted focus to address unmet needs in infectious diseases and oral health.
Core Business Areas
- Anti-infectives: Developing proprietary antibiotic candidates to combat multi-drug resistant organisms.
- Oral Mucositis Treatment: Developing therapies to prevent and treat oral mucositis, a common and debilitating side effect of cancer treatment.
Leadership and Structure
The company has a board of directors and a management team led by a CEO. The specific structure is typical for a small biotechnology company, with functions like research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- AG013: AG013 is the company's treatment for oral mucositis. It is a Lactococcus lactis strain that expresses human Trefoil Factor 1, or TFF1. The total market for Oral Mucositis therapies is estimated to be in the billions. Key Competitors are Helsinn (Aloxi), Camurus (Episil), and BioAlliance Pharma (Sitavig). It has no significant market share as it is still in development
- Antibiotic Programs: Oragenics is also developing a class of novel antibiotics. Currently in preclinical stage, specific market share data is unavailable. Competitors vary depending on the specific antibiotic and target infection, and can include large pharmaceutical companies and specialized biotech firms.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk and high reward. There is a constant need to innovate and stay ahead of the competition while working through the rigorous process of regulatory and clinical trials.
Positioning
Oragenics is a small biotechnology company, positioned as an innovator in both the anti-infectives and oral mucositis space. Their success depends on the advancement of their clinical pipeline and securing partnerships.
Total Addressable Market (TAM)
The TAM for anti-infectives is substantial, driven by the growing threat of antibiotic resistance. The TAM for oral mucositis therapies is also significant due to the prevalence of cancer treatments causing this side effect. Oragenics' position is as a developer of novel treatments aimed at specific patient populations.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Potential for breakthrough therapies in unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Small market capitalization
- Stock dilution due to capital raises
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial data leading to increased investor confidence
- Government grants and funding for antibiotic development
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Inability to secure funding
Competitors and Market Share
Key Competitors
- HELSINN
- CAMURUS
- BIOALLIANCE
Competitive Landscape
Oragenics is a small player facing stiff competition from larger, more established companies. Their success depends on differentiation and innovation.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's pre-revenue status. Growth is tied to clinical trial advancement and partnerships.
Future Projections: Future growth projections depend on the success of the company's clinical pipeline and ability to secure funding. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives are typically focused on advancing their lead compounds, such as AG013, through clinical trials and exploring partnerships.
Summary
Oragenics Inc. is a development-stage biotechnology company focusing on anti-infectives and oral mucositis treatments. Its future depends on the success of its clinical trials and its ability to secure funding and partnerships. Oragenics faces stiff competition from established pharmaceutical companies and must overcome regulatory hurdles to bring its products to market. The company's small size and limited resources present significant challenges, but the potential for breakthrough therapies in unmet medical needs offers substantial opportunities. Success will require effective execution and strategic decision-making.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Third-party market research reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share is estimated and can vary. The user should verify all the information before making any decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oragenics Inc
Exchange NYSE MKT | Headquaters Sarasota, FL, United States | ||
IPO Launch date 2004-02-25 | CEO, President, CFO, Secretary & Treasurer Ms. Janet Huffman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.oragenics.com |
Full time employees 3 | Website https://www.oragenics.com | ||
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.